Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment

Archives of Neurology

Volumn 62, Issue 6, 2005, Pages 975-980

  Devanand, D P ^a,b,d   Pelton, Gregory H ^a   Zamora, Diana ^a   Liu, Xinhua ^a   Tabert, Matthias H ^a   Goodkind, Madeleine ^a   Scarmeas, Nikolaos ^b,c,d   Braun, Ilana ^a   Stern, Yaakov ^b,c,d   Mayeux, Richard ^b,c,d  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE   (United States)

^c Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; APOLIPOPROTEIN E;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; OUTCOMES RESEARCH; OUTPATIENT; PREDICTION; PRIORITY JOURNAL; RECALL; AMBULATORY CARE; COMPARATIVE STUDY; GENETICS; LONGITUDINAL STUDY; MIDDLE AGED; PREDICTION AND FORECASTING;

AGED; ALZHEIMER DISEASE; AMBULATORY CARE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 20844445775     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.6.975     Document Type: Article

References (41)

1. National Institute on Aging/Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet. 1996;347:1091-1095.
2. Hendrie HC. Epidemiology of dementia and Alzheimer's disease. Am J Geriatr Psychiatry. 1998;6(2 suppl 1):S3-S18.
3. Slooter AJ, Cruts M, Kalmjin S. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam study. Arch Neurol. 1998;55:964-968.
4. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274-1278.
5. Breitner JC, Wyse BW, Anthony JC. ApoE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology. 1999;53:321-331.
6. Tang MX, Stern Y, Marder K. The ApoE-epsilon4 allele and the risk of Alzheimer's disease among African Americans, whites, and Hispanics. JAMA. 1998;279:751-755.
7. Smith GE, Bohac DL, Waring SC. Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects. Neurology. 1998;50:355-362.
8. Small GW, Chen ST, Komo S. Memory self-appraisal in middle-aged and older adults with the apolipoprotein E-4 allele. Am J Psychiatry. 1999;156:1035-1038.
9. Winnock M, Letenneur L, Jacqmin-Gadda H. Longitudinal analysis of the effect of apolipoprotein E ε4 and education on cognitive performance in elderly subjects: the PAQUID study. J Neurol Neurosurg Psychiatry. 2002;72:794-797.
10. Wilson RS, Schneider JA, Barnes LL. The apolipoprotein E-ε4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol. 2002;59:1154-1160.
11. Bretsky P, Guralnik JM, Launer L. The role of ApoE-ε4 in longitudinal cognitive decline. Neurology. 2003;60:1077-1081.
12. Yip AG, Brayne C, Easton D. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. J Med Genet. 2002;39:639-643.
13. Hyman BT, Gomez-Isla T, Briggs M. Apolipoprotein E and cognitive changes in an elderly population. Ann Neurol. 1996;40:55-66.
14. Jonker C, Schmand B, Lindeboom J. Association between apolipoprotein Eε4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol. 1998;55:1065-1069.
15. Yaffe K, Cauley J, Snads L. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol. 1997;54:1110-1114.
16. Dik MG, Jonker C, Comijs HC. Memory complaints and ApoE-ε4 accelerate cognitive decline in cognitively normal elderly. Neurology. 2001;57:2217-2222.
17. Myers RH, Schaefer EJ, Wilson PW. Apolipoprotein E-ε4 association with dementia in a population-based study: the Framingham study. Neurology. 1996;46:673-677.
18. Growdon JH, Locascio JJ, Corkin S. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology. 1996;47:444-448.
19. Juva K, Viramo P, Polvikoski T. ApoE epsilon-4 does not predict mortality, cognitive decline or dementia in the oldest old. Neurology. 2000;54:412-415.
20. Mayeux R, Small SA, Tang MX, Tycko B, Stern Y. Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E. Neurobiol Aging. 2001;22:683-689.
21. Stern Y, Brandt J, Albert M. The absence of apolipoprotein epsilon4 allele is associated with more aggressive form of Alzheimer's disease. Ann Neurol. 1997;41:615-620.
22. Mayeux R, Saunders AM, Shea S. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med. 1998;338:506-511.
23. Tierney MC, Szalai JP, Snow WG. A prospective study of the clinical utility of ApoE genotype in the predication of outcome in patients with memory impairment. Neurology. 1996;46:149-154.
24. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797-811.
25. Devanand DP, Folz M, Gorlyn M, Moeller JR, Stern Y. Questionable dementia: clinical course and predictors of outcome. J Am Geriatr Soc. 1997;45:321-328.
26. Artero S, Tierney MC, Touchon J, Ritchie K. Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr Scand. 2003;107:390-393.
27. Jacobs DM, Sano M, Dooneief G, Marder K, Bell KL, Stern Y. Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology. 1995;45:957-962.
28. Devanand DP, Michaels-Marston KS, Liu X, et al. Olfactory deficits in mild cognitive impairment predict Alzheimer's disease on follow-up. Am J Psychiatry. 2000;157:1399-1405.
29. Tabert MH, Albert SM, Borukhova-Milov L. Functional deficits in patients with mild cognitive impairment. Neurology. 2002;58:758-764.
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
31. Gilewski MJ, Zelinski EM, Schaie K. The memory functioning questionnaire for assessment of memory complaints in adulthood and old age. Psychol Aging. 1990;5:482-490.
32. Zelinski EM, Gilewski MJ, Anthony-Bergstone CR. Memory Functioning Questionnaire: concurrent validity with memory performance and self-reported memory failures. Psychol Aging. 1990;5:388-399.
33. Pfeffer RI, Kurosaki CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323-329.
34. Sano M, Devanand DP, Richards M, et al. A standardized technique for establishing onset and duration of symptoms of Alzheimer's disease. Arch Neurol. 1995;52:961-966.
35. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhAI. J Lipid Res. 1990;31:545-548.
36. Caselli RJ, Graff-Radford NR, Reiman EM. Preclinical memory decline in cognitively normal apolipoprotein E-ε4 homozygotes. Neurology. 1999;53:201-207.
37. O'Hara R, Yesavage JA, Kraemer HC. The apoE epsilon4 allele is associated with decline on delayed recall performance in community-dwelling older adults. J Am Geriatr Soc. 1998;46:1493-1498.
38. Hirono N, Hashimoto M, Yasuda M. Accelerated memory decline in Alzheimer's disease with apolipoprotein epsilon4 allele. J Neuropsychiatry Clin Neurosci. 2003;15:354-358.
39. Albert MS. Cognitive and neurobiologic markers of early Alzheimer disease. Proc Natl Acad Sci U S A. 1996;93:13547-13551.
40. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC; Cache County Study Investigators. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the Cache County Study. Arch Gen Psychiatry. 2004;61:518-524.
41. Saunders AM, Hulette C, Welsh-Bohmer KA. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet. 1996;348:90-93.